コントラフェクト（CFRX）ContraFect Corporation - 米国株銘柄紹介 | 米国株を知る場所 nasdaqchart（ナスダックチャート）

CFRXのチャート

CFRXの企業情報

symbol	CFRx
会社名	ContraFect Corp （コントラフェクト）
分野（sector）	Health Care ヘルスケア
産業（industry）	Major Pharmaceuticals
業種	バイオテクノロジ―_メディカルリサ―チ医療関連（Health Care）
概要	事業概要コントラフェックト（ContraFect Corporation）はバイオテクノロジー企業である。同社は、治療用タンパク質、入院を必要とする生命を脅かす薬剤耐性感染症のための抗体製品の発見及び開発に焦点を当てる。同社は、細菌やウイルスの保存領域（変異を起こしにくい領域）を標的とするリジンとモノクローナル抗体のプラットフォームからの治療薬候補を使用し、薬剤耐性感染症に対処する。同社の製品候補は、黄色ブドウ球菌菌血症の治療のためのリジン「CF-301」、生命を脅かす季節性及びパンデミック・インフルエンザの治療のためのmAbの組み合わせ「CF-404」を含む。「CF-301」と「CF-302」は、黄色ブドウ球菌感染症に対して強力な活性を持つバクテリオファージリシンである。コントラフェクトは治療用タンパク質と抗体の開発に焦点を置く米国のバイオ医薬品会社。細菌細胞壁を消化するリシン(タンパク質構成アミノ酸)とモノクロ―ナ抗体を開発。黄色ブドウ球菌菌血症、肺炎、骨髄炎、感染性心内膜炎の治療用リシンCF301の治験を行う。また、インフルエンザに対するモノクロ―ナ抗体の開発を行う。 ContraFect is a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. The Company intends to address life threatening infections using its therapeutic product candidates from its platform of DLAs, which include lysins and amurin peptides. Lysins are a new class of DLAs which are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the rapid killing of target bacteria, eradication of biofilms and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs which exhibit broad-spectrum activity against a wide range of antibiotic-resistant Gram-negative pathogens, including P. aeruginosa, Acinetobacter baumannii, and Enterobacter species. The Comapny believes that the properties of its lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, such as MRSA and P. aeruginosa, which can cause serious infections such as bacteremia, pneumonia and osteomyelitis. It has completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with its lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase, currently being studied in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the FDA for the treatment of MRSA bloodstream infections, including right-sided endocarditis, when used in addition to SOC anti-staphylococcal antibiotics in adult patients.
本社所在地	28 Wells Avenue Third Floor Yonkers NY 10701 USA
代表者氏名	Steven C. Gilman スティーブンC.ギルマン
代表者役職名	Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者
電話番号	+1 914-207-2300
設立年月日	39508
市場名	NASDAQ Small Cap
ipoyear	2014年
従業員数	－
url	www.contrafect.com
nasdaq_url	https://www.nasdaq.com/symbol/cfrx
adr_tso	―
EBITDA	EBITDA（百万ドル） -28.45300
終値（lastsale）	1.85
時価総額（marketcap）	146907678.6
時価総額	時価総額（百万ドル） 149.29000
売上高	売上高（百万ドル） 0.00000
企業価値(EV)	企業価値(EV)（百万ドル） 115.99598
当期純利益	当期純利益（百万ドル） -45.57498
決算概要	決算概要 BRIEF: For the six months ended 30 June 2018 ContraFect Corp revenues was not reported. Net loss increased from $9.2M to $39.2M. Higher net loss reflects Change in fair value of warrant liabilit decrease from $3.1M (income) to $25.1M (expense) General and administrative increase of 1% to $4.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.22 to -$0.53.

CFRXのテクニカル分析

CFRXのニュース

ContraFect Announces 7.03M Share Offering by Selling Stockholders 2023/04/28 20:26:01 Investing.com

https://www.investing.com/news/assorted/contrafect-announces-703m-share-offering-by-selling-stockholders-432SI-3068028

What''s Going On With ContraFecta Stock Today 2023/04/27 18:24:49 Benzinga

ContraFect Corporation (NASDAQ: CFRX ) shares are trading higher Thursday morning. However, there is no specific news to justify the move. Wednesday morning, ContraFect announced the dosing of the first patient in Phase 1b/2 of exebacase in the setting of an … Full story available on Benzinga.com

Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday''s Mid-Day Session 2023/04/27 16:48:47 Benzinga

Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO ) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its EDP1815 Phase 2 trial, in which the primary endpoint was not met. ContraFect Corporation (NASDAQ: CFRX ) gained 87% to $2.4693. ContraFect said first patient was dosed in the Phase 1b/2 study of exebacase in patients with chronic prosthetic joint infections of the knee. Hillstream BioPharma, Inc. (NASDAQ: HILS ) jumped 56% to $1.10. TOP Financial Group Limited (NASDAQ: TOP ) rose 53.7% to $10.33. U Power Limited (NASDAQ: UCAR ) climbed 33.5% to $5.45 after declining around 27% on Wednesday. Atomera Incorporated (NASDAQ: ATOM ) shares gained 23.6% to $6.45 after the company posted results for its first quarter. The company announced the execution of a commercial license agreement with STMicroelectronics (ST) that enables the latter to install Atomera''s Mears Silicon Technology into its facilities.

MBLY, NUWE and OMQS among mid-day movers 2023/04/27 16:24:19 Seeking Alpha

Gainers: TOP Financial Group Limited TOP +186%.Evelo Biosciences EVLO +184%.ContraFect Corporation CFRX +68%.U Power Limited Ordinary Shares (UCAR) +40%.Atomera Incorporated…

MBLY, NUWE and OMQS among mid-day gainers 2023/04/27 16:24:19 Seeking Alpha